Creative Medical Technology Holdings, Inc. - Common Stock (CELZ)

Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQCELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024.

Numerous companies merit attention at present due to recent developments. This feature offers a brief overview of five such companies.

Creative Medical Technology Holdings, Inc., (NASDAQCELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals.

Creative Medical Technology Holdings, Inc. (NASDAQCELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels.

PHOENIX, AZ / ACCESSWIRE / August 24, 2023 / Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQCELZ) seems to be witnessing success in the allogeneic cell therapy market.

PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQCELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™. This study aims to determine the safety, efficacy and tolerability of CELZ-201-DDT, a proprietary, ready-to-use cell line developed by the company.

PHOENIX, AZ / ACCESSWIRE / July 13, 2023 / Creative Medical Technology Holdings, Inc. ("Creative Medical Technology") (NASDAQCELZ) recently released an update on their drug pipeline and financial standing going into Q3 2023. The biotechnology company is known for its regenerative approach to immunotherapy, endocrinology, urology, gynecology and orthopedics.

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQCELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has engaged Syneos Health NASDAQ: SYNHNASDAQSYNH)

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQCELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced positive three-year follow-up data for the Company's StemSpine® pilot study. The three-year data demonstrates continued efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

Creative Medical Technology Holdings (NASDAQCELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, has entered into a securities purchase agreement. The agreement with several institutional investors to purchase more than 7.5 million shares of common stock or common stock equivalents in a private placement. The shares will be priced at market value. In addition, Creative Medical Technology will issue unregistered warrants to the investors, enabling them to purchase up to 15,111,112 shares of common stock. According to the agreement, those shares will be offered at $2.25 per share. The announcement noted that the warrants, which will expire five years after being issued, have an exercise price of $2 per share and are immediately exercisable. The company anticipates gross proceeds from the private placement to be approximately $17 million. According to the announcement, Roth Capital Partners acted as the sole placement agent for the offering, which closed on May 3, 2022.

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diagnosed with breast cancer across the globe, the need […]